A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01).

Keun-Wook LeeChi Hoon MaengTae-You KimDae Young ZangYeul Hong KimIn Gyu HwangSang Cheul OhJoo Seop ChungHong Suk SongJin Won KimSu Jin JeongJae Yong Cho

Published in: The oncologist (2018)

Although paclitaxel showed numerically longer PFS and OS compared with irinotecan, this was statistically insignificant. Both irinotecan and paclitaxel are valid second-line treatment options in MRGC.

Keyphrases

phase iii
open label
clinical trial
double blind
stem cells
mesenchymal stem cells